Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01828034
Title First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center, Novartis
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.